Novavax Q2 Revenue Misses, Loss Widens, but Guidance Raised on Sanofi, Pfizer Deals
NVAX sits 25% above its 52-week low of $6.2.
Summary
Novavax reported a 76% drop in Q2 revenue to $56.7M and a net loss of $53.4M, but raised its full-year revenue guidance to $235M-$275M, supported by Sanofi and Pfizer partnerships. Cash reserves of $723.9M and a new credit facility provide near-term stability.
Key Events · Earnings and Guidance · NVAX
-
Q2 Revenue Plunges 76%
Total revenue fell to $56.7M from $239.2M in Q2 2025, driven by the absence of large APA termination payments and milestone revenues that boosted the prior-year period.
-
Net Loss of $53.4M
Novavax swung to a net loss of $53.4M, or $0.32 per share, compared to net income of $106.5M a year ago, as operating expenses of $111.6M exceeded revenue.
-
Full-Year Guidance Raised
Management increased the 2026 adjusted revenue forecast to $235M-$275M from $230M-$270M, citing growing royalties and cost reimbursements from Sanofi and the new Pfizer license.
-
Cash Runway and Going Concern
Cash and marketable securities totaled $723.9M as of June 30, 2026. The company concluded it has sufficient capital to fund operations for at least the next 12 months, removing near-term going concern risk.
Analysis · NVAX · Life Sciences
Second-quarter revenue at Novavax tumbled 76% to $56.7 million from $239.2 million a year ago, and the company swung to a net loss of $53.4 million. The sharp decline reflects the non-recurrence of large APA termination payments and milestone revenues that boosted 2025 results. Despite the top-line miss, management raised its full-year 2026 adjusted revenue forecast to $235–$275 million, citing growing royalties and cost reimbursements from the Sanofi partnership and the new $30 million Pfizer license deal. The balance sheet remains strained with a $190.7 million stockholders' deficit, but $723.9 million in cash and securities and a new $330 million credit facility provide runway. The going concern evaluation concluded the company has sufficient capital for at least the next 12 months. Key catalysts ahead include a potential $125 million milestone from Sanofi's CIC Phase 3 trial initiation and a $75 million payment upon manufacturing tech transfer completion in mid-2027.
At the time of this filing, NVAX was trading at $7.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $6.20 to $11.97. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.